The CIHR is funding clinical trials through its Operating Grants for Psilocybin-assisted Psychotherapy for Mental Health and Substance Use Disorders VANCOUVER, BC, July 6, 2023 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical–stage natural psychedelic drug development company, today announced that it will supply psilocybin for two clinical…

Source

Previous articleSmall Pharma Announces SPL028 R&D Strategy Update
Next articlePT421 – The Impact of the Therapeutic Alliance on the Psychedelic Experience